Anti-CD3 Induced Cytokine Release Syndrome

Description

The anti-CD3 induced cytokine release syndrome (CRS) model is commonly used to evaluate T cell mediated cytokine storm. Similar to sepsis, disease is characterized by upregulation of pro-inflammatory cytokines. In rodents, anti-CD3 elicits a strong immune response within hours following administration. This response is measured by examining IFN-γ, IL-6, TNF-α, or other pro-inflammatory cytokine concentrations in blood plasma/serum. Compounds which prevent the elevation of cytokines are predicted to offer protection against CRS.

  • Advantages: acute response, well-published.
Model Systems
  • BALB/c Mice
Standard Readouts
  • Plasma/serum cytokines
Additional Readouts
  • Peripheral blood/lymphoid organ immunophenotyping
  • Custom assays
Representative DataClick Image to Enlarge
Plasma Cytokines in the anti-CD3 induced Cytokine Release Model

Animals with OXZ-induced colitis are weighed daily, and body weight change as compared to baseline is calculated. The AUC is calculated to compare treatment arms and is shown in the inset. (**p<0.01 compared to the Naive).

Daniel Lichtman

Managing Partner